Search

everythinglearnresearchcommunity

for

Search:↓

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

A 19-year-old male plans to start finasteride due to hair thinning after using creatine. He seeks advice on finasteride's effectiveness, especially for Asians.

A user found a red light cap from China with good specifications for hair loss treatment, priced at €480. They seek opinions on its legitimacy and quality, especially from those with experience ordering from AliExpress.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

The conversation discusses the difference in attitudes toward hair loss treatments, with a focus on lifestyle changes and hair transplant surgery in Hong Kong, as opposed to treatments like minoxidil, finasteride, and microneedling discussed on 'tresless'. The user is now using finasteride and minoxidil and considering microneedling.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

A 23-year-old Asian male shared progress pictures after 3 months of using minoxidil, microneedling for 1.5 years, and taking vitamin supplements. Replies suggest adding finasteride or dutasteride for long-term hair maintenance.

PCOS female visited doctor for hair loss concerns, prescribed spironolactone and minox 5%. Doctor advised against finasteride or dutasteride, user considering self-medication with dutasteride.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

User Kylo313 used dutasteride for 20 years and had two daughters, questioning if dutasteride affects the likelihood of having male vs female children. Replies mostly request hairline photos and discuss anecdotal experiences, with some suggesting correlation doesn't imply causation and that gender determination isn't affected by dutasteride.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.